Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYP17A1 is a critical steroidogenic enzyme that catalyzes 17α-hydroxylation and C17,20-lyase reactions, essential for glucocorticoid, androgen, and estrogen production. It is a therapeutic target, particularly in prostate cancer, and mutations can cause congenital disorders of steroidogenesis.
Inhibition of androgen synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1).